Recipharm notes an increased demand for Chloroquine Phosphate
Recipharm, a leading contract development and manufacturing organisation (CDMO), has recently noted an increase in demand for its product Klorokinfosfat RPH Pharma marketed in Sweden by Astimex Pharma. The CDMO has also received questions about the product, which is typically used to treat patients with malaria prophylaxis and rheumatoid arthritis. The reason for the interest in this well-known product is due to chloroquine's antiviral effects, which mean it has been mentioned as a drug that can potentially be used when treating patients with coronavirus COVID-19 associated pneumonia.